retatrutide phase 2 trial obesity nejm 2023 triple agonist This week's most cited articles: 1. Original Article: Triple–Hormone-Receptor for — A https://t.co/jNL1GNnHPT #Endocrinology Retatrutide just delivered the first
Description
The STEP 4 trial published in JAMA showed that participants maintained significant weight loss over 68 weeks when continuing the medication
doi: 10.1007/s00429-014-0841-6
Vos, and C
What to Keep in Mind When Considering GLP-1s Adding any medication to your treatment plan is a big decision, especially when you have bipolar disorder
It felt like whiplash for Ms
